A Meta-Analysis of Missing Data and Non-Compliance Data in Clinical Endpoint Bioequivalence Studies

Statistics in Biopharmaceutical Research

Volumn 8, Issue 3, 2016, Pages 334-344

  Sun, Wanjie ^a   Zhou, Lingjie ^b   Grosser, Stella ^a   Kim, Carol ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Bioequivalence; Meta analysis; Missing data; Non compliance data

Indexed keywords

ARTICLE; BIOASSAY; BIOEQUIVALENCE; DATA ANALYSIS; DROP OUT; DRUG USE; HUMAN; INFLAMMATORY LESION COUNT; LOGISTIC REGRESSION ANALYSIS; MATHEMATICAL PARAMETERS; MATHEMATICAL PHENOMENA; META ANALYSIS; META ANALYSIS (TOPIC); MISSING DATA; MODEL; NON COMPLIANCE DATA; NONINFLAMMATORY LESION COUNT; POPULATION; SENSITIVITY ANALYSIS; SUPERIORITY TEST;

EID: 84988019245     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2016.1201000     Document Type: Article

References (18)

1. W.G.Cochran, (1954), “The Combination of Estimates from Different Experiments,” Biometrics, 10, 101–129.
2. B.M.Davit, P.E.Nwakama, G.J.Buehler, D.P.Conner, S.H.Haidar, D.T.Patel, Y.Yang, Y.Lawrence, and J.Woodcock, (2009), “Comparing Generic and Innovator Drugs:A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration,” The Annals of Pharmacotherapy, 43, 1583–1597.
3. E.C.Fieller, (1940), “The Biological Standardization of Insulin,” Supplement to the Journal of the Royal Statistical Society, 7, 1–64.
4. ——— (1954), “Some Problems in Interval Estimation,” Journal of the Royal Statistical Society, Series B 16, 175–185.
5. A.Heyting, J.T.B.M.Tolboom, and J.G.A.Essers, (1992), “Statistical Handling of Drop‐Outs in Longitudinal Clinical Trials,” Statistics in Medicine, 11, 2043–2061.
6. M.Jaeger, (2006), “On Testing the Missing at Random Assumption,” in Machine Learning:ECML, Springer Berlin Heidelberg, pp. 671–678.
7. L.M.LaVange, and T.Permutt, (2015), “A Regulatory Perspective on Missing Data in the Aftermath of the NRC Report,” Statistics in Medicine, 17Dec2015 published online. DOI:10.1002/sim.6840.
8. R.J.Little, (1993), “Pattern-Mixture Models for Multivariate Incomplete Data,” Journal of American Statistician Association, 88, 125–134.
9. R.J.Little, R.D'Agostino, M.L.Cohen, K.Dickersin, S.S.Emerson, J.T.Farrar, C.Frangakis, J.W.Hogan, G.Molenberghs, S.A.Murphy, and J.D.Neaton, (2012), “The Prevention and Treatment of Missing Data in Clinical Trials,” New England Journal of Medicine, 367, 1355–1360.
10. R.J.Little, and D.B.Rubin, (2002), Statistical Analysis With Missing Data (2nd ed.), Hoboken, NJ:Wiley.
11. Panel on Handling Missing Data in Clinical Trials; National Research Council CNSTAT & DBASSE. (2010), The Prevention and Treatment of Missing Data in Clinical Trials, Washington, DC:The National Academies Press.
12. T.Permutt, (2015a), “A Taxonomy of Estimands for Regulatory Clinical Trials With Discontinuations,” Statistics in Medicine. 17Dec2015 published online. DOI:10.1002/sim.6841.
13. ——— (2015b), “Sensitivity Analysis for Missing Data in Regulatory Submissions,” Statistics in Medicine. 15Dec2015 published online. DOI:10.1002/sim.6753.
14. D.B.Rubin, (1976), “Inference and Missing Data,” Biometrika, 63, 581–592.
15. D.Schuirmann, (1987), “A Comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability,” Journal of Pharmacokinetics and Biopharmaceutics, 15, 657–680.
16. A.Whitehead, (2002), Meta-Analysis of Controlled Clinical Trials (1st ed.), Hoboken, NJ:Wiley.
17. A.Whitehead, and J.Whitehead, (1991), “A General Parametric Approach to the Meta‐Analysis of Randomized Clinical Trials,” Statistics in Medicine, 10, 1665–1677.
18. L.Yu, Li. (2014), FDA Bioequivalence Standards, New York:Springer. 248–250.